BRPI0821315A2 - compostos benzimidazol - Google Patents

compostos benzimidazol

Info

Publication number: BRPI0821315A2
Authority: BR; Brazil
Prior art keywords: benzimidazole compounds; benzimidazole; compounds
Prior art date: 2007-12-21

Application number

BRPI0821315A

Other languages

English (en)

Inventor

Harry Kaufman David

E Wrobel Jay

Mark Travins Jeremy

Charles Bernotas Ronald

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-21

Filing date

2008-12-19

Publication date

2019-09-24

2008-12-19 Application filed by Wyeth Llc filed Critical Wyeth Llc

2019-09-24 Publication of BRPI0821315A2 publication Critical patent/BRPI0821315A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0821315A 2007-12-21 2008-12-19 compostos benzimidazol BRPI0821315A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1607007P	2007-12-21	2007-12-21
PCT/US2008/087735 WO2009086138A1 (en)	2007-12-21	2008-12-19	Benzimidazole compounds

Publications (1)

Publication Number	Publication Date
BRPI0821315A2 true BRPI0821315A2 (pt)	2019-09-24

Family

ID=40386193

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0821315A BRPI0821315A2 (pt)	2007-12-21	2008-12-19	compostos benzimidazol

Country Status (9)

Country	Link
US (1)	US20110034526A1 (pt)
EP (1)	EP2231617A1 (pt)
JP (1)	JP2011507905A (pt)
CN (1)	CN101952257A (pt)
AU (1)	AU2008345696A1 (pt)
BR (1)	BRPI0821315A2 (pt)
CA (1)	CA2710461A1 (pt)
MX (1)	MX2010007019A (pt)
WO (1)	WO2009086138A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013130892A1 (en)	2012-03-02	2013-09-06	Anayaderm, Inc.	Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
ES2941477T3 (es)	2012-08-13	2023-05-23	Univ Rockefeller	Agonista de LXRbeta para el tratamiento de cáncer
EP3041834A4 (en)	2013-09-04	2017-01-18	Ralexar Therapeutics, Inc.	Liver x receptor (lxr) modulators
CA2923175C (en)	2013-09-04	2022-07-26	Alexar Therapeutics, Inc.	Liver x receptor (lxr) modulators
EP2860177A3 (en)	2013-09-20	2015-06-10	Bayer Intellectual Property GmbH	Synthesis of functionalized arenes
AU2015204572B2 (en)	2014-01-10	2020-07-30	Inspirna, Inc.	LXR agonists and uses thereof
AU2017207291B2 (en)	2016-01-11	2023-06-15	The Rockefeller University	Methods for the treatment of myeloid derived suppressor cells related disorders
CN106083729A (zh) *	2016-07-01	2016-11-09	王建军	一种苯并咪唑类化合物的合成方法
JP2021504315A (ja)	2017-11-21	2021-02-15	ルジェニクス，インコーポレーテッド	多形及びその使用
CN110372524B (zh) *	2019-06-26	2022-08-30	天津理工大学	一种以联二萘胺为母核的三苯胺类有机空穴传输材料及其的合成及其用途
CN112341429B (zh) *	2019-08-09	2021-11-23	成都先导药物开发股份有限公司	一种免疫调节剂的中间体化合物
EP4073025B1 (en)	2019-12-13	2024-03-27	Inspirna, Inc.	Metal salts and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2795730B1 (fr) *	1999-07-01	2001-08-31	Adir	Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20040259948A1 (en) *	2003-01-10	2004-12-23	Peter Tontonoz	Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
US7245483B2 (en) *	2003-07-18	2007-07-17	Satori Labs, Inc.	Integrated personal information management system
PE20050676A1 (es) *	2003-12-12	2005-11-02	Wyeth Corp	Quinolinas referidas a enfermedades cardiovasculares
PL1996556T3 (pl) *	2005-12-05	2010-05-31	Neurosearch As	Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA
TWI391381B (zh) *	2006-03-24	2013-04-01	Neurosearch As	新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
US20080070883A1 (en) *	2006-09-19	2008-03-20	Wyeth	Use of LXR modulators for the prevention and treatment of skin aging

2008
- 2008-12-19 BR BRPI0821315A patent/BRPI0821315A2/pt not_active IP Right Cessation
- 2008-12-19 US US12/809,873 patent/US20110034526A1/en not_active Abandoned
- 2008-12-19 AU AU2008345696A patent/AU2008345696A1/en not_active Abandoned
- 2008-12-19 CA CA2710461A patent/CA2710461A1/en not_active Abandoned
- 2008-12-19 MX MX2010007019A patent/MX2010007019A/es not_active Application Discontinuation
- 2008-12-19 EP EP08867575A patent/EP2231617A1/en not_active Withdrawn
- 2008-12-19 CN CN2008801273634A patent/CN101952257A/zh active Pending
- 2008-12-19 JP JP2010539886A patent/JP2011507905A/ja not_active Withdrawn
- 2008-12-19 WO PCT/US2008/087735 patent/WO2009086138A1/en active Application Filing

Also Published As

Publication number	Publication date
EP2231617A1 (en)	2010-09-29
JP2011507905A (ja)	2011-03-10
US20110034526A1 (en)	2011-02-10
WO2009086138A1 (en)	2009-07-09
CA2710461A1 (en)	2009-07-09
CN101952257A (zh)	2011-01-19
AU2008345696A1 (en)	2009-07-09
MX2010007019A (es)	2010-08-18

Publication	Publication Date	Title
LTPA2020528I1 (lt)	2020-09-25	Benzimidazolo dariniai
BRPI0821315A2 (pt)	2019-09-24	compostos benzimidazol
BRPI0813500A2 (pt)	2015-01-06	Compostos antivirais
DK2288375T3 (da)	2012-05-21	Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt)	2015-12-29	compostos
BRPI0821086A2 (pt)	2014-10-07	Compostos inseticidas
DK2242759T3 (da)	2012-12-17	Forbindelser
ATE502948T1 (de)	2011-04-15	Substituierte bicyclolactamverbindungen
BR112012010502A2 (pt)	2016-03-15	derivados de benzimidazol-imidazol
BRPI0906705A2 (pt)	2015-06-30	Composto heterocíclicos
BRPI0811264A2 (pt)	2014-11-04	Compostos
DK2323972T3 (da)	2013-10-07	C7-fluor-substituerede tetracylinforbindelser
DK2308869T3 (da)	2012-10-08	Azolforbindelse
FI20070694A0 (fi)	2007-09-11	Hissijärjestely
EP2088861A4 (en)	2010-07-07	Benzimidazole compounds
FI20070924A0 (fi)	2007-11-30	Hissin valmiustila
DK2297162T3 (da)	2012-11-26	Forbindelser
BRPI0814424A2 (pt)	2015-01-06	Compostos heterociclila
BRPI0809996A2 (pt)	2014-10-14	Compostos
BRPI0916432A2 (pt)	2016-02-16	compostos
BRPI0922098A2 (pt)	2015-12-15	composto inorgânicos
BRPI0923592A2 (pt)	2016-01-26	composto
BRPI0815181A2 (pt)	2015-03-31	Compostos
DK2206698T3 (da)	2012-08-27	Ethynylindolforbindelser
BRPI0922152A2 (pt)	2015-08-18	Compostos

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.